Recursion Pharmaceuticals Long Term Debt

Recursion Pharmaceuticals posts a long-term debt of $50M as of March 2026. That compares with $72M in the prior-year period — down 31.0% year over year. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.

In the prior comparable period, Recursion Pharmaceuticals's long-term debt was $72M. The latest reading is $50M — a 31.0% year-over-year decrease (period ending March 2026). Use the history and growth charts on this page for a longer lookback.

Long-Term Debt is one piece of Recursion Pharmaceuticals's financial statement story. At $50M, it should be interpreted next to related metrics — for example revenue with costs, assets with liabilities, or income with margins. Stockcircle links those related pages so you can move from this number to the surrounding context quickly.

Context for RXRX's long-term debt usually means three checks: (1) trend versus prior periods, (2) level versus peers, and (3) consistency with growth and profitability. This page covers the first two; Recursion Pharmaceuticals's other metric pages and overview cover the third.

Judging Recursion Pharmaceuticals against Healthcare peers is usually better than using a market-wide rule of thumb. Business models inside Healthcare are more comparable, which makes gaps in long-term debt easier to interpret. Start with $50M here, then scan peer and history charts to see if the gap is persistent.